Hey mate,
You must have forgotten about the $5M allocation by the BOD to the Aprix portfolio.
This will be sufficient for the next two years as part of the two-year overall development funding program from the current cash in the bank.
I agree that Bob Clark's efforts to sell a part of the IHL portfolio will have a big impact on our ability to fund future trials and research into 2024-5.
So assuming that the Resolution is passed at today's AGM. Bob Clarke will have 382 trading days (not including 78 Saturdays, 78 Sundays and 12 public holidays) to do a deal with Big Pharma.
As I said previously, income from Big Pharma for IHL-42X (sleep Apnoea) could bring in the $1-3 per share range (my preference would be for the BOD to hold IHL-675 for the longer term)
Big Pharma will be falling over themselves to get a piece of IHL-42X, once we get some positive data readouts in the coming few months or so.
I don't think Bob's task will be too difficult and his options will be pretty safe IMO.
Once we get a sale locked away by May '24 (just 550 calendar days away - haha) Incannex will be the darling stock on the ASX.
Well done BOD for adding another pipeline to the back end of our development program, this therapy could produce another $1 or so per share (if sold) to our cash at the bank around 2025/6
GLAH
